British Journal of Oral and Maxillofacial Surgery
Volume 46, Issue 5 , Pages 370-375 , July 2008

Predicting recurrence after oral precancer treatment: Use of cell cycle analysis

  • P.J. Thomson

      Affiliations

    • Oral & MaxilloFacial Surgery, School of Dental Sciences, Newcastle University, UK
    • ,
  • O. Hamadah

      Affiliations

    • Oral & MaxilloFacial Surgery, School of Dental Sciences, Newcastle University, UK
    • Corresponding Author InformationCorresponding author. Oral & MaxilloFacial Surgery, School of Dental Sciences, Framlington Place, Newcastle upon Tyne, NE2 4BW, UK. Tel.: +44 191 222 8290; fax: +44 191 222 6137.
    • ,
  • M.L. Goodson

      Affiliations

    • Oral & MaxilloFacial Surgery, School of Dental Sciences, Newcastle University, UK
    • ,
  • N. Cragg

      Affiliations

    • Epistem Ltd, Incubator Building, Grafton Street, Manchester, UK
    • ,
  • C. Booth

      Affiliations

    • Epistem Ltd, Incubator Building, Grafton Street, Manchester, UK

,Accepted 2 January 2008.

References 

  1. Llewellyn CD, Linklater K, Bell J, Johnson NW, Warnakulasuriya S. An analysis of risk factors for oral cancer in young people: a case-control study. Oral Oncol. 2004;40:304–313
  2. Thomson PJ, Goodson ML, Booth C, Cragg N, Hamadah O. Cyclin A activity predicts clinical outcome in oral precancer and cancer. Int J Oral Maxillofac Surg. 2006;35:1041–1046
  3. Thomson PJ, Wylie J. Interventional laser surgery: an effective surgical and diagnostic tool in oral precancer management. Int J Oral Maxillofac Surg. 2002;31:145–153
  4. Epstein JB, Zhang L, Rosin M. Advances in the diagnosis of oral premalignant and malignant lesions. J Can Dent Assoc. 2002;68:617–621
  5. Warnakulasuriya S. Histological grading of oral epithelial dysplasia: revisited. The J Pathol. 2001;194:294–297
  6. Scully C. Oral precancer: preventive and medical approaches to management. Eur J Cancer. 1995;3:16–26
  7. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14:47–62
  8. Lind PO. Malignant transformation in oral leukoplakia. Scand J Dent Res. 1987;95:449–455
  9. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol. 1998;34:270–275
  10. Hsue SS, Wang WC, Chen CH, Lin CC, Chen YK, Lin LM. Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med. 2007;36:25–29
  11. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol. 2006;42:461–474
  12. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Interventions for treating oral leukoplakia. Cochrane database of systematic reviews (Online) 2006; CD001829.
  13. Thomson PJ, Potten CS, Appleton DR. Characterization of epithelial cell activity in patients with oral cancer. Br J Oral Maxillofac Surg. 1999;37:384–390
  14. Thomson PJ, Soames JV, Booth C, O'Shea JA. Epithelial cell proliferative activity and oral cancer progression. Cell Prolif. 2002;35(Suppl 1):110–120
  15. Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis?. Int J Oral Maxillofac Surg. 2002;3:262–266
  16. Lotayef M, Wilson GD, Daley FM, Awwad HK, Shouman T. Aberrant expression of cyclin A in head and neck cancer. Br J Cancer. 2000;83:30–34
  17. Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer. 2002;86:402–408
  18. Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res. 2000;7:2458–2462
  19. Kushner J, Bradley G, Young B, Jordan RC. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J Oral Pathol Med. 1999;28:77–81
  20. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60:4000–4004
  21. Egloff A, Vella L A, OJ. F. Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer. Cancer Res 2006; 66: 6–9.
  22. Macluskey M, Ogden GR, Green M, Chisholm DM, Schor SL, Schor AM. The association between epithelial proliferation and disease progression in the oral mucosa. Oral oncol. 1999;35:409–414
  23. Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med. 2003;14:363–369
  24. Thomson PJ, Hamadah O. Cancerisation within the oral cavity: The use of ’field mapping biopsies’ in clinical management. Oral oncol. 2007;43:20–26
  25. Thomas G, Hashibe M, Jacob BJ, Ramadas K, Mathew B, Sankaranarayanan R, et al. Risk factors for multiple oral premalignant lesions. Int J Cancer. 2003;107:285–291

PII: S0266-4356(08)00007-7

doi: 10.1016/j.bjoms.2008.01.003

British Journal of Oral and Maxillofacial Surgery
Volume 46, Issue 5 , Pages 370-375 , July 2008

Article Tools

* Image Usage & Resolution